These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24071596)

  • 1. Changing presentation of prostate cancer in a UK population--10 year trends in prostate cancer risk profiles in the East of England.
    Greenberg DC; Wright KA; Lophathanon A; Muir KR; Gnanapragasam VJ
    Br J Cancer; 2013 Oct; 109(8):2115-20. PubMed ID: 24071596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic characteristics of lethal prostate cancer.
    Helgstrand JT; Røder MA; Klemann N; Toft BG; Brasso K; Vainer B; Iversen P
    Eur J Cancer; 2017 Oct; 84():18-26. PubMed ID: 28779631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing.
    Pashayan N; Powles J; Brown C; Duffy SW
    Br J Cancer; 2006 Aug; 95(3):398-400. PubMed ID: 16832416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
    Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
    World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
    Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
    BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unintended consequences of decreased PSA-based prostate cancer screening.
    Ahlering T; Huynh LM; Kaler KS; Williams S; Osann K; Joseph J; Lee D; Davis JW; Abaza R; Kaouk J; Patel V; Kim IY; Porter J; Hu JC
    World J Urol; 2019 Mar; 37(3):489-496. PubMed ID: 30003374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent trends in prostate cancer incidence and mortality in southeast England.
    Evans HS; Møller H
    Eur Urol; 2003 Apr; 43(4):337-41. PubMed ID: 12667713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
    Moore AL; Dimitropoulou P; Lane A; Powell PH; Greenberg DC; Brown CH; Donovan JL; Hamdy FC; Martin RM; Neal DE
    BJU Int; 2009 Dec; 104(11):1592-8. PubMed ID: 19549125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
    Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
    Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
    KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
    BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Patient Demographic Characteristics and Radiation Timing on PSA Reduction in Patients Treated With Definitive Radiation Therapy for Prostate Cancer.
    Gupta A; Vernali S; Rand AE; Agarwal A; Qureshi MM; Hirsch AE
    Clin Genitourin Cancer; 2015 Aug; 13(4):364-369. PubMed ID: 25766484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in stage-specific incidence of prostate cancer in Norway, 1980-2010: a population-based study.
    Møller MH; Kristiansen IS; Beisland C; Rørvik J; Støvring H
    BJU Int; 2016 Oct; 118(4):547-55. PubMed ID: 26497872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).
    Schröder F; Bangma C; Angulo JC; Alcaraz A; Colombel M; McNicholas T; Tammela TL; Nandy I; Castro R
    Eur Urol; 2013 May; 63(5):779-87. PubMed ID: 23176897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
    Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
    Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
    Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gleason inflation 1998-2011: a registry study of 97,168 men.
    Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
    BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
    Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
    Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
    Kelly SP; Anderson WF; Rosenberg PS; Cook MB
    Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.